Chemomab Therapeutics logo

Chemomab TherapeuticsNASDAQ: CMMB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

12 February 2019

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$29.98 M
-71%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 22:22:08 GMT
$1.59-$0.07(-4.22%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CMMB Latest News

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
globenewswire.com12 August 2024 Sentiment: POSITIVE

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.

Chemomab Therapeutics Announces $10 Million Private Placement
globenewswire.com25 July 2024 Sentiment: POSITIVE

Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.

Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
zacks.com27 June 2024 Sentiment: POSITIVE

Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
globenewswire.com06 June 2024 Sentiment: POSITIVE

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation— —New Translational Data Further Confirms CM-101's Disease Modifying Activity in Primary Sclerosing Cholangitis— TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it presented two scientific posters supporting the clinical rationale for the company's primary sclerosing cholangitis (PSC) program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy.

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
globenewswire.com17 May 2024 Sentiment: POSITIVE

Chemomab Therapeutics Ltd., a biotechnology company working on treatments for fibro-inflammatory diseases, will be presenting at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
Zacks Investment Research16 November 2023 Sentiment: POSITIVE

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript
Seeking Alpha14 May 2023 Sentiment: POSITIVE

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.

What type of business is Chemomab Therapeutics?

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

What sector is Chemomab Therapeutics in?

Chemomab Therapeutics is in the Healthcare sector

What industry is Chemomab Therapeutics in?

Chemomab Therapeutics is in the Biotechnology industry

What country is Chemomab Therapeutics from?

Chemomab Therapeutics is headquartered in Israel

When did Chemomab Therapeutics go public?

Chemomab Therapeutics initial public offering (IPO) was on 12 February 2019

What is Chemomab Therapeutics website?

https://www.chemomab.com

Is Chemomab Therapeutics in the S&P 500?

No, Chemomab Therapeutics is not included in the S&P 500 index

Is Chemomab Therapeutics in the NASDAQ 100?

No, Chemomab Therapeutics is not included in the NASDAQ 100 index

Is Chemomab Therapeutics in the Dow Jones?

No, Chemomab Therapeutics is not included in the Dow Jones index

When was Chemomab Therapeutics the previous earnings report?

No data

When does Chemomab Therapeutics earnings report?

The next expected earnings date for Chemomab Therapeutics is 07 March 2025